DeepMed Research

Tilarginine

Generic Name: Tilarginine

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₆N_₄O_₂

CAS Number: 17035-90-4

Unique Ingredient Identifier: 27JT06E6GR

Background: Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

Clinical Trials

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Metastatic Breast Cancer
Metaplastic Breast Carcinoma
TNBC - Triple-Negative Breast Cancer

Interventions: Drug: L-NMMA

First Posted Date: 2022-12-21

Last Posted Date: 2025-05-16

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 36

Registration Number: NCT05660083

Locations: 🇺🇸
National Institute of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation

Recruiting

Conditions: Aging
Cardiovascular Disease

Interventions: Drug: NG-Monomethyl-L-Arginine

First Posted Date: 2018-08-10

Last Posted Date: 2025-01-07

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 130

Registration Number: NCT03625349

Locations: 🇺🇸
VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

Phase 2

Completed

Conditions: Hyperlipidemias

Interventions: Drug: Teduglutide + Normal Saline
Drug: Teduglutide + L-NMMA
Drug: Placebo + L-NMMA

First Posted Date: 2018-05-23

Last Posted Date: 2020-03-27

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT03534661

Locations: 🇨🇦
Tornto General Hospital, UHN, Toronto, Ontario, Canada

Phase Ib of L-NMMA and Pembrolizumab

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer
DNA Repair-Deficiency Disorders
Urothelial Carcinoma Bladder
Malignant Melanoma
Classical Hodgkin Lymphoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: L-NMMA
Drug: Pembrolizumab

First Posted Date: 2017-08-02

Last Posted Date: 2025-03-10

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 12

Registration Number: NCT03236935

Locations: 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Phase 1

Withdrawn

Conditions: Hypoxia
Hypercapnia

Interventions: Drug: L-NMMA
Drug: Ketorolac
Drug: Ascorbic Acid
Procedure: Intravenous Catheter
Procedure: Transcranial Doppler Ultrasound

First Posted Date: 2017-02-28

Last Posted Date: 2019-01-10

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT03066115

Locations: 🇺🇸
University of Wisconsin, Madison, Madison, Wisconsin, United States

Mechanisms of Cerebrovascular Control

Phase 1

Completed

Conditions: Metabolic Syndrome X

Interventions: Drug: ET-1 Inhibition
Drug: NOS Inhibition
Drug: NOS Inhibition Placebo
Device: 3 Tesla MRI
Device: Intravenous Catheter
Other: Oral Glucose Tolerance Test
Drug: ET-1 Inhibition Placebo

First Posted Date: 2016-10-18

Last Posted Date: 2021-10-18

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 59

Registration Number: NCT02936687

Locations: 🇺🇸
University of Wisconsin, Madison, Madison, Wisconsin, United States

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Phase 1

Completed

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Drug: L-NMMA
Drug: Docetaxel
Drug: Amlodipine
Drug: Pegfilgrastim
Drug: Enteric-coated aspirin

First Posted Date: 2016-07-15

Last Posted Date: 2023-12-15

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 37

Registration Number: NCT02834403

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

PORH and Response to Cold in Raynaud's Phenomenon.

Not Applicable

Conditions: Hyperemia
Raynaud Disease
Cold

Interventions: Procedure: post-occlusive hyperemia
Procedure: cooling box
Drug: L-NMMA and Fluconazole dermic injection

First Posted Date: 2014-07-08

Last Posted Date: 2015-12-09

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 60

Registration Number: NCT02183779

Locations: 🇫🇷
Centre d'investigation clinique CIC1406, GRENOBLE cedex9, France

Plasma Triglyceride Extraction by The Muscle

Phase 1

Completed

Conditions: Insulin Resistance
Obesity

Interventions: Drug: Insulin
Drug: NG-monomethyl-L-arginine

First Posted Date: 2013-05-23

Last Posted Date: 2021-10-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 33

Registration Number: NCT01860911

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Exenatide placebo
Drug: Liraglutide placebo
Drug: Liraglutide
Drug: Sitagliptin
Drug: Exenatide
Drug: Sitagliptin placebo
Drug: L-NMMA

First Posted Date: 2012-12-06

Last Posted Date: 2015-12-09

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 70

Registration Number: NCT01744236

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy